CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
PharmaCHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. is a pharmaceutical company focused on Oncology, Respiratory, Infectious Disease.
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. at a Glance
- Growing R&D activity with 59 trials in last 2 years
- Fast trial execution (19 months median completion)
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.'s Key Drugs
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.'s key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.'s Recent FDA Approvals
New NDA/BLA approvals for CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. over the last two years — novel drugs only, excluding generics and label supplements.
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.'s Therapeutic Areas
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.'s approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.'s Top Competitors
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.'s closest competitors by therapeutic-area and drug-target overlap include GSK, Merck, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Pipeline Snapshot
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. has 130 active clinical programs from ClinicalTrials.gov — 21 Phase 3, 42 Phase 2 and 67 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/23 completed
- • Speed: 19 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- -
- Latest
- -
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges